Shashi Adsul

Statistics

Publications

Citations

430

H-Index

Active since

2018

Affiliations

Takeda (Switzerland)(Current)

Takeda (United States)

Icahn School of Medicine at Mount Sinai

Nutrition-Génétique et Exposition aux Risques Environnementaux

Inserm

Shashi Adsul is an author at Takeda (Switzerland) specializing in inflammatory bowel disease, inflammatory bowel disease therapy, and vedolizumab therapy.

ORCID

Publications per year

2018–2024

Publications

Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting

Siew C. Ng, Ida Hilmi, Aimee Blake et al. · Inflammatory Bowel Diseases · 2018 · 95 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn’s Disease: ENTERPRISE Study

David A. Schwartz, Laurent Peyrin‐Biroulet, Karen Lasch et al. · Clinical Gastroenterology and Hepatology · 2021 · 81 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial

Vipul Jairath, Guangyong Zou, Zhongya Wang et al. · BMJ Open Gastroenterology · 2024 · 38 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16

Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions

Mathieu Uzzan, Yoram Bouhnik, María T. Abreu et al. · Journal of Crohn s and Colitis · 2023 · 36 citations

Medicine, Internal Medicine, Clinical Trial Regulation +15

An artificial intelligence‐driven scoring system to measure histological disease activity in ulcerative colitis

Laurent Peyrin‐Biroulet, Shashi Adsul, Andrea Stancati et al. · United European Gastroenterology Journal · 2024 · 27 citations · Full text

Medicine, Computer Science, Pathology +17

1–5 of 13